Friday, 16 October 2026European Markets

SATS Stock Impressive Rise 14% So Far On Wednesday, Outperforms Market

Loading stream...

(VIANEWS) - Shares of SATS (Oslo Børs Benchmark Index_GI: SATS.OL) rose by a staggering 14.13% to kr10.26 at 11:37 EST on Wednesday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 0.78% to kr1,214.04, following the last session's downward trend. This seems, at the moment, a somewhat positive trend exchanging session today.

SATS's last close was kr8.99, 50.6% below its 52-week high of kr18.20.

About SATS

Sats ASA provides fitness and training services in Norway, Sweden, Denmark, and Finland. The company offers sportswear, fitness gear, bars, and energy drinks. It operates 262 fitness clubs under the SATS, ELIXIA, Fresh Fitness, HiYoga, and Mentra brands. The company was founded in 1995 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, SATS has a trailing twelve months EPS of kr-0.89.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -36.63%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SATS's stock is considered to be oversold (<=20).

Moving Average

SATS's worth is way above its 50-day moving average of kr7.95 and way higher than its 200-day moving average of kr8.97.

Volatility

SATS's last week, last month's, and last quarter's current intraday variation average was 0.98%, 1.28%, and 2.28%.

SATS's highest amplitude of average volatility was 1.78% (last week), 2.14% (last month), and 2.28% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 8%, now sitting on 4.08B for the twelve trailing months.

More news about SATS (SATS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com